<div id="readability-page-1"><p>In a report released today, Anthony Petrone from Mizuho Securities reiterated a Buy rating on Pulse Biosciences, with a price target of <span id="expert-recommendation-target">$30.00</span>.</p><h3>President's Day Sale - 70% Off</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>According to TipRanks, Petrone is a 4-star analyst with an average return of <span>7.3%</span> and a 50.11% success rate. Petrone covers the Healthcare sector, focusing on stocks such as Pulse Biosciences, Haemonetics, and Dexcom.</p> <p>In addition to Mizuho Securities, Pulse Biosciences also received a Buy from TipRanks – Google’s Google Medical – Instruments and Supplies in a report issued today. However, on the same day, TipRanks – OpenAI reiterated a Hold rating on Pulse Biosciences (NASDAQ: PLSE).</p></div>

SBIO

PLSE

<p>Mizuho Securities has maintained a Buy rating on Pulse Biosciences (PLSE) with a price target of $30. Analyst Anthony Petrone, noted for a 7.3% average return and a 50.11% success rate, focuses on the Healthcare sector. Additionally, TipRanks also issued a Buy rating for Pulse Biosciences, while another report from TipRanks reiterated a Hold rating on the same stock.</p>

Tip Ranks

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Health Equip

Proshares Ultra Nasdaq Biotech

Pulse Biosciences

iShares US Medical Devices

Mizuho Securities Sticks to Their Buy Rating for Pulse Biosciences (PLSE)